Siliconizing Fluids
Ellsworth Adhesive Co XIAMETER PMX-200 SILICON 500ML
XIAMETER™ PMX-200 Silicone Fluid 2 cSt 500 ML Bottle
Medchemexpress LLC PMX 205 Trifluoroacetate | 99.5% | 953.06 | 100 MG
PMX 205 Trifluoroacetate is identified as a specific complement C5aR1 isoform antagonist. It is intended for research use only and is not sold to patients.
- Specific complement C5aR1 isoform antagonist.
- Orally active, selective C5aR antagonist.
- Extends survival time and reduces end-stage motor scores in SOD1G93A rats.
- Reduces astroglial proliferation in the lumbar spinal cord.
- Decreases fibrillar plaque load in Tg2576 mice.
- Significantly reduces hyperphosphorylated tau in 3xTg mice.
Medchemexpress LLC KY-556 | 110816-78-9 | 725.57 | 1 ML
KY-556 is a promising and orally-active pro-agent of disodium cromoglycate (DSCG) against allergic diseases. This solution is for research use only.
- Orally-active pro-agent against allergic diseases
- Provided as a 10 mM solution in 1 mL DMSO
- Ready for reconstitution
- In-stock
Medchemexpress LLC hsa-miR-556-5p mimic 20nmol | 20nmol
hsa-miR-556-5p mimics are small chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity
Medchemexpress LLC L-Arginine, N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl- | 514814-49-4 | 99.5% | 839.04 | 1 ML
PMX 205 is a potent complement C5a receptor (C5aR; CD88) antagonist.
- Recruits and activates microglia and astrocytes in vitro by activating a G protein-coupled cell-surface C5aR.
- Shows significant results in MTT assays at 24 h, 48 h, and 72 h incubation times.
- Orally active, selective C5aR antagonist.
- Extends survival time, reduces end-stage motor scores, and decreases astroglial proliferation in animals.
- Reduces fibrillar plaque load and hyperphosphorylated tau in murine models of Alzheimer's disease.
Medchemexpress LLC L-Arginine, N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl-, (5→1)-lactam | 514814-49-4 | 99.5% | 839.04 | 50 MG
PMX 205 is a potent and orally active complement C5a receptor (C5aR; CD88) antagonist. This selective antagonist is extensively used in research for its biological activities and therapeutic potential across various disease models.
- Potent and selective complement C5a receptor (C5aR; CD88) antagonist.
- Orally active for convenience in in vivo studies.
- Demonstrated extended survival and reduced motor decline in neurological disease models.
- Reduced astroglial proliferation in spinal cord.
- Decreased fibrillar plaque load and hyperphosphorylated tau in Alzheimer's disease models.
- Blocked C5a-induced cellular expression changes and proliferation.
- Exhibited suppression of GPX4 expression and inhibition of tumor growth in specific studies.
Medchemexpress LLC PMX 205 Trifluoroacetate | 99.5% | 953.06 | 100 MG
PMX 205 Trifluoroacetate is a specific complement C5aR1 isoform antagonist.
- Specific complement C5aR1 isoform antagonist
- Orally active
- Extends survival time and reduces end-stage motor scores in a rat model of amyotrophic lateral sclerosis
- Reduces astroglial proliferation in the lumbar spinal cord
- Decreases fibrillar plaque load and reduces hyperphosphorylated tau in murine models of Alzheimer's disease
- Available in various quantities and forms
Apexbio Technology LLC PMX 205 Trifluoroacetate 514814-49-4 (free base) 5mg
PMX 205 Trifluoroacetate is a cyclic hexapeptide antagonist targeting the complement C5a receptor (C5aR CD88) It is designed to competitively inhibit C5a binding to its receptor thereby modulating complement-mediated inflammatory pathways PMX 205 Trifluoroacetate exerts its biological activity primarily through competitive antagonism at C5aR reducing downstream inflammatory cellular responses In animal models PMX 205 Trifluoroacetate demonstrates anti-inflammatory effects Based on these pharmacological properties PMX 205 Trifluoroacetate holds research potential in the study of neuroinflammation Alzheimer s disease and chemically induced colitis
Selleck Chemical LLC PMX-53
PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM respectively PMX-53 is also an agonist of Mas-related gene 2 (MrgX2)
Medchemexpress LLC L-Arginine, N2-(1-oxo-3-phenylpropyl)-L-ornithyl-L-prolyl-3-cyclohexyl-D-alanyl-L-tryptophyl | 514814-49-4 | MFCD31657373 | >98.0% | 839.04 g/mol | C45H62N10O6 | 5 MG
PMX 205 is a cyclic peptide research compound that acts as a potent antagonist of the complement C5a receptor (C5aR; CD88). It is supplied for laboratory research use only, and is characterized by a molecular formula of C45H62N10O6 and a molecular weight of 839.04 g/mol. The product is offered in multiple pack sizes, including milligram quantities and a 10 mM solution in DMSO, and is accompanied by product datasheet and COA documentation.